RVL Pharmaceuticals plc RVLPQ

RVLPQ Company Overview

RVL Pharmaceuticals plc was a specialty pharmaceutical company focused on the commercialization of ophthalmic products in the United States. The company’s primary commercial asset was Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%), a prescription eye drop approved by the U.S. Food and Drug Administration for the treatment of acquired blepharoptosis, commonly referred to as low-lying eyelids, in adults. The company operated within the branded pharmaceutical and eye-care sectors, targeting ophthalmologists, oculoplastic surgeons, optometrists, and aesthetic medicine providers.

The company evolved from a development-stage pharmaceutical business into a commercial-stage specialty pharma company after obtaining regulatory approval for Upneeq in 2020. RVL Pharmaceuticals emphasized physician-directed commercialization and direct engagement with eye-care specialists rather than broad primary-care distribution. Public filings and restructuring disclosures indicate the company later experienced financial distress related to commercialization costs, liquidity constraints, and debt obligations, ultimately leading to restructuring proceedings and over-the-counter trading under the ticker RVLPQ.